FindTrial
Sign In

Dose fractionation study of pancreatic cancer treated by Cyberknife

Dose fractionation study of pancreatic cancer treated by Cyberknife

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-POD-17011953
Enrollment
Unknown
Registered
2017-07-12
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancratic cancer

Interventions

study group:hypofractional radiotherapy 40Gy/8F
compare group:hypofractional radiotherapy 50Gy/10F

Sponsors

302 hospital of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. pancreatic cancer confirmed by biopsy; 2. the diameter of single tumor less than equal to 5cm; 3. ECOG score is 0-1; 4. normal pretreatment blood counts and renal and liver function test; 5. unresectable lesion comfirmed by multidisciplinary team(MDT); 6. a life expectancy of at least 6 months.

Exclusion criteria

Exclusion criteria: 1. heart,lung or kidney dysfunction; 2. abnormal function of liver and kidney; 3. mental disorder; 4. tumor metastasis; 5. abdominal radiotherapy history; 6. with serious medical diseases.

Design outcomes

Primary

MeasureTime frame
overall survival rate;local control rate;—

Secondary

MeasureTime frame
The incidence of 2-4 grade gastrointestinal toxicity;The incidence of 2-4 grade hematologic toxicity;CEA;CA19-9;Quality of life;—

Countries

China

Contacts

Public ContactXuezhang Duan

302 hospital of PLA

13621386161@163.com+86 13621386161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026